SEngine Precision Medicine to Present Data on Predictive Value of PARIS® Test in Ovarian Cancer Patients at 2021 AACR Annual ...
SEATTLE, March 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today announced that data from a study summarizing the predictive …